Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.

By D. Andes, N. Safdar, J. Baddley, G. Playford, A. Reboli, J. Rex, J. Sobel, P. Pappas, B. Kullberg. Clinical Infectious Diseases, 2012

759 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients (2016, background): “Twenty-two major publications were identified (Tables 2 and 3).(5-26) Fifteen reported primary results from clinical trials.”
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. (2016, background): “Most experts agree that thoughtful patientspecific management of CVCs is critical in the overall management of the infection [19].”
ESCMID guideline for the diagnosis and treatment of biofilm infections 2014. (2015, background): “because non-removal is associated with an increased mortality and a more prolonged candidaemia [16,102,162,175–182].”